High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Knowledge of “actionable” somatic genomic alterations present in each tumor (e.g., point mutations, small insertions/deletions, and copy-number alterations that direct therapeutic options) should facilitate individualized approaches to cancer treatment. However, clinical implementation of systematic genomic profiling has rarely been achieved beyond limited numbers of oncogene point mutations. To address this challenge, we utilized a targeted, massively parallel sequencing approach to detect tumor genomic alterations in formalin-fixed, paraffin-embedded (FFPE) tumor samples. Nearly 400-fold mean sequence coverage was achieved, and single-nucleotide sequence variants, small insertions/deletions, and chromosomal copynumber alterations were detected simultaneously with high accuracy compared with other methods in clinical use. Putatively actionable genomic alterations, including those that predict sensitivity or resistance to established and experimental therapies, were detected in each tumor sample tested. Thus, targeted deep sequencing of clinical tumor material may enable mutation-driven clinical trials and, ultimately, “personalized” cancer treatment. Significance: Despite the rapid proliferation of targeted therapeutic agents, systematic methods to profile clinically relevant tumor genomic alterations remain underdeveloped. We describe a sequencing-based approach to identifying genomic alterations in FFPE tumor samples. These studies affirm the feasibility and clinical utility of targeted sequencing in the oncology arena and provide a foundation for genomics-based stratification of cancer patients. Cancer Discovery; 2(1); 82–93. ©2011 AACR. Read the Commentary on this article by Corless and Spellman, p. 23 This article is highlighted in the In This Issue feature, p. 1
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
Self-citationInhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Stratton, M. R., Campbell, P. J., & Futreal, P. A. (2009) · Nature · doi:10.1038/nature07943 · Cited by 3,449
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278 · cited 5×
“The BATTLE Trial: Personalizing Therapy for Lung Cancer”
MethodInfluentialDe Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Berns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.030 · Cited by 1,627
Garraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., Beroukhim, R., Milner, D. A., Granter, S. R., Du, J., et al. (2005) · Nature · doi:10.1038/nature03664 · Cited by 1,548
Self-citationGnirke, A., Melnikov, A., Maguire, J., Rogov, P., LeProust, E. M., Brockman, W., Fennell, T., Giannoukos, G., Fisher, S., Russ, C., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1523 · Cited by 1,433
Self-citationFinn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Cited by
Frampton, G. M., Fichtenholtz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., Schnall-Levin, M., White, J., Sanford, E. M., An, P., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2696 · Cited by 2,157
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0099 · Cited by 1,641
“55(0) 42(11) 20(32) 11(41) 6(44) 2(47) 0(49) 3(4) 0(6) 0(6) 0(6) 0(6) 0(6)”
Lessons from the Cancer Genome
Garraway, L. A., & Lander, E. S. (2013) · Cell · doi:10.1016/j.cell.2013.03.002 · Cited by 1,308
Self-citationForshew, T., Murtaza, M., Parkinson, C., Gale, D., Tsui, D. W. Y., Kaper, F., Dawson, S.-J., Piskorz, A. M., Jimenez-Linan, M., Bentley, D., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003726 · Cited by 1,297
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Toy, W., Shen, Y., Won, H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K., Fanning, S., King, T. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2822 · Cited by 1,248
Self-citationTumour heterogeneity in the clinic
Bedard, P. L., Hansen, A. R., Ratain, M. J., & Siu, L. L. (2013) · Nature · doi:10.1038/nature12627 · Cited by 1,211
The Genetic Evolution of Melanoma from Precursor Lesions
Shain, A. H., Yeh, I., Kovalyshyn, I., Sriharan, A., Talevich, E., Gagnon, A., Dummer, R., North, J., Pincus, L., Ruben, B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502583 · Cited by 1,065
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations
Lindsley, R. C., Mar, B. G., Mazzola, E., Grauman, P. V., Shareef, S., Allen, S. L., Pigneux, A., Wetzler, M., Stuart, R. K., Erba, H. P., et al. (2015) · Blood · doi:10.1182/blood-2014-11-610543 · Cited by 991
Next-generation sequencing technologies: An overview
Hu, T., Chitnis, N., Monos, D., & Dinh, A. (2021) · Human Immunology · doi:10.1016/j.humimm.2021.02.012 · Cited by 949
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0714 · Cited by 945
“Alternative multigene, next-generation sequencing assays are also offered in several cancer centers in the United States and routinely include assessment of core HR genes (53).”
BackgroundIntegrative clinical genomics of metastatic cancer
Robinson, D. R., Wu, Y.-M., Lonigro, R. J., Vats, P., Cobain, E., Everett, J., Cao, X., Rabban, E., Kumar-Sinha, C., Raymond, V., et al. (2017) · Nature · doi:10.1038/nature23306 · Cited by 863
“It was among the first comprehensive, clinical DNA and RNA sequencing programs offered for cancer patients 8,12–16 .”
(2017) · doi:10.1158/1078-0432.ccr-16-3133 · Cited by 831
The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
Helsten, T., Elkin, S., Arthur, E., Tomson, B. N., Carter, J., & Kurzrock, R. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3212 · Cited by 808
Awad, M. M., Oxnard, G. R., Jackman, D. M., Savukoski, D. O., Hall, D., Shivdasani, P., Heng, J. C., Dahlberg, S. E., Jänne, P. A., Verma, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.4600 · Cited by 693
Seiwert, T. Y., Zuo, Z., Keck, M. K., Khattri, A., Pedamallu, C. S., Stricker, T., Brown, C., Pugh, T. J., Stojanov, P., Cho, J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3310 · Cited by 657
The emerging clinical relevance of genomics in cancer medicine
Berger, M. F., & Mardis, E. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0002-6 · Cited by 626
Self-citationStrickland, K. C., Howitt, B. E., Shukla, S. A., Rodig, S., Ritterhouse, L. L., Liu, J. F., Garber, J. E., Chowdhury, D., Wu, C. J., D’Andrea, A. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7277 · Cited by 620
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Juric, D., Castel, P., Griffith, M., Griffith, O. L., Won, H. H., Ellis, H., Ebbesen, S. H., Ainscough, B. J., Ramu, A., Iyer, G., et al. (2015) · Nature · doi:10.1038/nature13948 · Cited by 588
Self-citationVan Allen, E. M., Wagle, N., Stojanov, P., Perrin, D. L., Cibulskis, K., Marlow, S., Jane-Valbuena, J., Friedrich, D. C., Kryukov, G., Carter, S. L., et al. (2014) · Nature Medicine · doi:10.1038/nm.3559 · Cited by 546
Self-citationGarcia, E. P., Minkovsky, A., Jia, Y., Ducar, M. D., Shivdasani, P., Gong, X., Ligon, A. H., Sholl, L. M., Kuo, F. C., MacConaill, L. E., et al. (2017) · Archives of Pathology and Laboratory Medicine · doi:10.5858/arpa.2016-0527-oa · Cited by 524
Self-citationLi, T., Kung, H.-J., Mack, P. C., & Gandara, D. R. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.3753 · Cited by 518
Institutional implementation of clinical tumor profiling on an unselected cancer population
Sholl, L. M., Do, K., Shivdasani, P., Cerami, E., Dubuc, A. M., Kuo, F. C., Garcia, E. P., Jia, Y., Davineni, P., Abo, R. P., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.87062 · Cited by 450
Self-citationPersonalized genomic analyses for cancer mutation discovery and interpretation
Jones, S., Anagnostou, V., Lytle, K., Parpart-Li, S., Nesselbush, M., Riley, D. R., Shukla, M., Chesnick, B., Kadan, M., Papp, E., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa7161 · Cited by 415
DGIdb 2.0: mining clinically relevant drug–gene interactions
Wagner, A. H., Coffman, A. C., Ainscough, B. J., Spies, N. C., Skidmore, Z. L., Campbell, K. M., Krysiak, K., Pan, D., McMichael, J. F., Eldred, J. M., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1165 · Cited by 413
“The Foundation One (19) diagnostic test focuses on clinically actionable genes, and DGIdb 2.0 uses the data from this source as a new ‘clinically actionable’ druggable gene category.”
BackgroundInfluentialAndré, F., Bachelot, T., Commo, F., Campone, M., Arnedos, M., Dieras, V., Lacroix-Triki, M., Lacroix, L., Cohen, P., Gentien, D., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70611-9 · Cited by 404
Microsatellite Instability Detection by Next Generation Sequencing
Salipante, S. J., Scroggins, S. M., Hampel, H. L., Turner, E. H., & Pritchard, C. C. (2014) · Clinical Chemistry · doi:10.1373/clinchem.2014.223677 · Cited by 399
A targeted mutational landscape of angioimmunoblastic T-cell lymphoma
Odejide, O., Weigert, O., Lane, A. A., Toscano, D., Lunning, M. A., Kopp, N., Kim, S., van Bodegom, D., Bolla, S., Schatz, J. H., et al. (2014) · Blood · doi:10.1182/blood-2013-10-531509 · Cited by 398
DNA sequencing technologies: 2006–2016
Mardis, E. R. (2017) · Nature Protocols · doi:10.1038/nprot.2016.182 · Cited by 395
Chang, K., Bai, H. X., Zhou, H., Su, C., Bi, W. L., Agbodza, E., Kavouridis, V. K., Senders, J. T., Boaro, A., Beers, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2236 · Cited by 391
Genetic alterations defining NSCLC subtypes and their therapeutic implications
Pikor, L. A., Ramnarine, V. R., Lam, S., & Lam, W. L. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.07.025 · Cited by 375
Best practices for variant calling in clinical sequencing
Koboldt, D. C. (2020) · Genome Medicine · doi:10.1186/s13073-020-00791-w · Cited by 384
Recurrent SMARCA4 mutations in small cell carcinoma of the ovary
Jelinic, P., Mueller, J. J., Olvera, N., Dao, F., Scott, S. N., Shah, R., Gao, J., Schultz, N., Gonen, M., Soslow, R. A., et al. (2014) · Nature Genetics · doi:10.1038/ng.2922 · Cited by 379
Self-citationStathis, A., Zucca, E., Bekradda, M., Gomez-Roca, C., Delord, J.-P., de La Motte Rouge, T., Uro-Coste, E., de Braud, F., Pelosi, G., & French, C. A. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1335 · Cited by 378
The Fanconi Anemia Pathway in Cancer
Niraj, J., Färkkilä, A., & D'Andrea, A. D. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050422 · Cited by 376
Tannir, N. M., Jonasch, E., Albiges, L., Altinmakas, E., Ng, C. S., Matin, S. F., Wang, X., Qiao, W., Dubauskas Lim, Z., Tamboli, P., et al. (2016) · European Urology · doi:10.1016/j.eururo.2015.10.049 · Cited by 364
The Implications of Clonal Genome Evolution for Cancer Medicine
Aparicio, S., & Caldas, C. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1204892 · Cited by 356
FunSeq2: A framework for prioritizing noncoding regulatory variants in cancer
Fu, Y., Liu, Z., Lou, S., Bedford, J., Mu, X., Yip, K. Y., Khurana, E., & Gerstein, M. (2014) · Genome Biology · doi:10.1186/preaccept-1739683221127290 · Cited by 352
Lin, J. J., Zhu, V. W., Yoda, S., Yeap, B. Y., Schrock, A. B., Dagogo-Jack, I., Jessop, N. A., Jiang, G. Y., Le, L. P., Gowen, K., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.2294 · Cited by 349
Next-generation sequencing in the clinic: Promises and challenges
Xuan, J., Yu, Y., Qing, T., Guo, L., & Shi, L. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.11.025 · Cited by 344
Genomics-Driven Oncology: Framework for an Emerging Paradigm
Garraway, L. A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.8934 · Cited by 340
Self-citationBreast cancer intra-tumor heterogeneity
Martelotto, L. G., Ng, C. K., Piscuoglio, S., Weigelt, B., & Reis-Filho, J. S. (2014) · Breast Cancer Research · doi:10.1186/bcr3658 · Cited by 332
Hiatt, J. B., Pritchard, C. C., Salipante, S. J., O'Roak, B. J., & Shendure, J. (2013) · Genome Research · doi:10.1101/gr.147686.112 · Cited by 327
Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence
Nissan, M. H., Pratilas, C. A., Jones, A. M., Ramirez, R., Won, H., Liu, C., Tiwari, S., Kong, L., Hanrahan, A. J., Yao, Z., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2625 · Cited by 319
Self-citationImplementing personalized cancer genomics in clinical trials
Simon, R., & Roychowdhury, S. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3979 · Cited by 301
DNA Source Selection for Downstream Applications Based on DNA Quality Indicators Analysis
Lucena-Aguilar, G., Sánchez-López, A. M., Barberán-Aceituno, C., Carrillo-Ávila, J. A., López-Guerrero, J. A., & Aguilar-Quesada, R. (2016) · Biopreservation and Biobanking · doi:10.1089/bio.2015.0064 · Cited by 286
Genomic Analysis of Metastatic Cutaneous Squamous Cell Carcinoma
Li, Y. Y., Hanna, G. J., Laga, A. C., Haddad, R. I., Lorch, J. H., & Hammerman, P. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1773 · Cited by 285
Shain, A. H., Garrido, M., Botton, T., Talevich, E., Yeh, I., Sanborn, J. Z., Chung, J., Wang, N. J., Kakavand, H., Mann, G. J., et al. (2015) · Nature Genetics · doi:10.1038/ng.3382 · Cited by 283
RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients
Kato, S., Subbiah, V., Marchlik, E., Elkin, S. K., Carter, J. L., & Kurzrock, R. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1679 · Cited by 282
Next-generation sequencing to guide cancer therapy
Gagan, J., & Van Allen, E. M. (2015) · Genome Medicine · doi:10.1186/s13073-015-0203-x · Cited by 280
Assessing the clinical utility of cancer genomic and proteomic data across tumor types
Yuan, Y., Van Allen, E. M., Omberg, L., Wagle, N., Amin-Mansour, A., Sokolov, A., Byers, L. A., Xu, Y., Hess, K. R., Diao, L., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.2940 · Cited by 280
Self-citationYaeger, R., Cercek, A., O'Reilly, E. M., Reidy, D. L., Kemeny, N., Wolinsky, T., Capanu, M., Gollub, M. J., Rosen, N., Berger, M. F., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2779 · Cited by 276
Self-citationPritchard, C. C., Salipante, S. J., Koehler, K., Smith, C., Scroggins, S., Wood, B., Wu, D., Lee, M. K., Dintzis, S., Adey, A., et al. (2014) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.08.004 · Cited by 273
A RAD 51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
Castroviejo‐Bermejo, M., Cruz, C., Llop‐Guevara, A., Gutiérrez‐Enríquez, S., Ducy, M., Ibrahim, Y. H., Gris‐Oliver, A., Pellegrino, B., Bruna, A., Guzmán, M., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201809172 · Cited by 268
Konstantinopoulos, P. A., Barry, W. T., Birrer, M., Westin, S. N., Cadoo, K. A., Shapiro, G. I., Mayer, E. L., O'Cearbhaill, R. E., Coleman, R. L., Kochupurakkal, B., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30905-7 · Cited by 263
Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas
Zhang, B., Chang, K., Ramkissoon, S., Tanguturi, S., Bi, W. L., Reardon, D. A., Ligon, K. L., Alexander, B. M., Wen, P. Y., & Huang, R. Y. (2017) · Neuro-Oncology · doi:10.1093/neuonc/now121 · Cited by 263
Wong, S. Q., Li, J., Tan, A. Y.-C., Vedururu, R., Pang, J.-M. B., Do, H., Ellul, J., Doig, K., Bell, A., McArthur, G. A., et al. (2014) · BMC Medical Genomics · doi:10.1186/1755-8794-7-23 · Cited by 247
“Many studies have reported the feasibility of using DNA from formalin-fixed material using both conventional PCR-based and MPS technologies [4,15,16].”
BackgroundNeoantigen identification strategies enable personalized immunotherapy in refractory solid tumors
Chen, F., Zou, Z., Du, J., Su, S., Shao, J., Meng, F., Yang, J., Xu, Q., Ding, N., Yang, Y., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci99538 · Cited by 229
“Targeted sequencing panels that query a subset of cancer-related genes have widely been implicated in cancer biology or clinical management (21, 31-34).”
BackgroundHarris, M. H., DuBois, S. G., Glade Bender, J. L., Kim, A., Crompton, B. D., Parker, E., Dumont, I. P., Hong, A. L., Guo, D., Church, A., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.5689 · Cited by 206
“Variant of uncertain significance 6 (15 [4-26])”
Self-citationTan, M. C., Basturk, O., Brannon, R. A., Bhanot, U., Scott, S. N., Bouvier, N., LaFemina, J., Jarnagin, W. R., Berger, M. F., Klimstra, D., et al. (2015) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2014.11.029 · Cited by 203
“High Throughput, Targeted Deep Sequencing Targeted, massively-parallel sequencing was then performed on a panel of 275 genes (including KRAS, GNAS and RNF43; see Appendix (available online) known to undergo somatic genomic alterations in cancer, as previously described(13,14).”
MethodSelf-citationYaeger, R., Shah, M. A., Miller, V. A., Kelsen, J. R., Wang, K., Heins, Z. J., Ross, J. S., He, Y., Sanford, E., Yantiss, R. K., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.04.001 · Cited by 200
High-throughput phenotyping of lung cancer somatic mutations
Berger, A. H., Brooks, A. N., Wu, X., Shrestha, Y., Chouinard, C., Piccioni, F., Bagul, M., Kamburov, A., Imielinski, M., Hogstrom, L., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.022 · Cited by 192
Self-citationThe NF1 gene revisited - from bench to bedside
Yap, Y.-S., McPherson, J. R., Ong, C.-K., Rozen, S. G., Teh, B.-T., Lee, A. S. G., & Callen, D. F. (2014) · Oncotarget · doi:10.18632/oncotarget.2194 · Cited by 189
“More recently, this Claudin-low subtype cell line was found to harbour NF1 mutation [118].”
BackgroundThe impact of tumor profiling approaches and genomic data strategies for cancer precision medicine
Garofalo, A., Sholl, L., Reardon, B., Taylor-Weiner, A., Amin-Mansour, A., Miao, D., Liu, D., Oliver, N., MacConaill, L., Ducar, M., et al. (2016) · Genome Medicine · doi:10.1186/s13073-016-0333-9 · Cited by 179
Self-citationLightbody, G., Haberland, V., Browne, F., Taggart, L., Zheng, H., Parkes, E., & Blayney, J. K. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bby051 · Cited by 173
“With the development of FFPE-tailored pre-processing pipelines alongside refinement in the underlying technologies, it is expected that HTS accuracy will potentially improve, enabling clinical uptake [105, 107].”
MethodPARP Inhibitors in Ovarian Cancer
Mittica, G., Ghisoni, E., Giannone, G., Genta, S., Aglietta, M., Sapino, A., & Valabrega, G. (2018) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892813666180305165256 · Cited by 158
Louissaint, A., Schafernak, K. T., Geyer, J. T., Kovach, A. E., Ghandi, M., Gratzinger, D., Roth, C. G., Paxton, C. N., Kim, S., Namgyal, C., et al. (2016) · Blood · doi:10.1182/blood-2015-12-682591 · Cited by 158
Self-citationLin, J. J., Choudhury, N. J., Yoda, S., Zhu, V. W., Johnson, T. W., Sakhtemani, R., Dagogo-Jack, I., Digumarthy, S. R., Lee, C., Do, A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0032 · Cited by 145
Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors
Kosaka, T., Tanizaki, J., Paranal, R. M., Endoh, H., Lydon, C., Capelletti, M., Repellin, C. E., Choi, J., Ogino, A., Calles, A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3404 · Cited by 131
Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2
Zhang, H., Fillmore Brainson, C., Koyama, S., Redig, A. J., Chen, T., Li, S., Gupta, M., Garcia-de-Alba, C., Paschini, M., Herter-Sprie, G. S., et al. (2017) · Nature Communications · doi:10.1038/ncomms14922 · Cited by 127
Calles, A., Sholl, L. M., Rodig, S. J., Pelton, A. K., Hornick, J. L., Butaney, M., Lydon, C., Dahlberg, S. E., Oxnard, G. R., Jackman, D. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3112 · Cited by 115
“To further study our LKB1 IHC assay using clinical samples, we tested a clinical set of KRAS-mutant NSCLC specimens that had undergone targetedNGS (36).”
MethodNetSig: network-based discovery from cancer genomes
Horn, H., Lawrence, M. S., Chouinard, C. R., Shrestha, Y., Hu, J. X., Worstell, E., Shea, E., Ilic, N., Kim, E., Kamburov, A., et al. (2018) · Nature Methods · doi:10.1038/nmeth.4514 · Cited by 105
“Therefore, it is a central aim of oncology to provide a complete catalogue of genes underlying human cancers 1–6 .”
Self-citationYaeger, R., Yao, Z., Hyman, D. M., Hechtman, J. F., Vakiani, E., Zhao, H., Su, W., Wang, L., Joelson, A., Cercek, A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0768 · Cited by 94
Self-citationPrecision Medicine for Continuing Phenotype Expansion of Human Genetic Diseases
Yu, H., & Zhang, V. W. (2015) · BioMed Research International · doi:10.1155/2015/745043 · Cited by 23
The Fuzzy World of Precision Medicine: Deliberations of a Precision Medicine Tumor Board
McGraw, S. A., Garber, J., Jänne, P. A., Lindeman, N., Oliver, N., Sholl, L. M., Van Allen, E. M., Wagle, N., Garraway, L. A., Joffe, S., et al. (2017) · Personalized Medicine · doi:10.2217/pme-2016-0074 · Cited by 20
Self-citationEthical considerations of neuro-oncology trial design in the era of precision medicine
Gupta, S., Smith, T. R., & Broekman, M. L. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2502-0 · Cited by 19
Boiarsky, D., Tewari, A. K., Gulhan, D. C., Bakouny, Z., Ananda, G., Savignano, H., Lakshminarayanan, G., McClure, H. M., Silver, R., Choueiri, T. K., et al. (2024) · The Prostate · doi:10.1002/pros.24788 · Cited by 4
“18 Sequence variants, copy ‐ number alterations, and structural variants were identified as previously described.”
Metadata
- Authors
- Wagle, N., Berger, M. F., Davis, M. J., Blumenstiel, B., DeFelice, M., Pochanard, P., Ducar, M., Van Hummelen, P., MacConaill, L. E., Hahn, W. C., Meyerson, M., Gabriel, S. B., & Garraway, L. A.
- Venue
- Cancer Discovery
- Published
- 2012-01-01
- Volume
- 2
- Issue
- 1
- Pages
- 82-93
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2130940380
- Cited by
- 533
- References
- 54
- FWCI
- 13.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.